Carisma Therapeutics, Inc. (CARM)
| Market Cap | 96.24K -99.2% |
| Revenue (ttm) | 52.63M +159.7% |
| Net Income | 8.04M |
| EPS | 0.19 |
| Shares Out | 41.85M |
| PE Ratio | 0.01 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,712 |
| Open | 0.0023 |
| Previous Close | 0.0023 |
| Day's Range | 0.0023 - 0.0023 |
| 52-Week Range | 0.0001 - 0.5560 |
| Beta | -28.88 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 20, 2026 |
About Carisma Therapeutics
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo... [Read more]
Financial Performance
In 2024, Carisma Therapeutics's revenue was $19.63 million, an increase of 31.59% compared to the previous year's $14.92 million. Losses were -$60.48 million, -30.39% less than in 2023.
Financial StatementsNews
ProKidney appoints Kenneth Locke as chief technical officer
ProKidney (PROK) announced the appointment of Kenneth Locke as chief technical officer. Locke joins ProKidney from Carisma Therapeutics (CARM), where he oversaw CMC, Quality and Regulatory functions a...
Carisma Therapeutics announces Nasdaq delisting, SEC deregistration
Carisma Therapeutics (CARM)’ Board of Directors has approved and the Company intends to proceed with the voluntary delisting of its common stock from The Nasdaq Stock Market and the deregistration…
Carisma Announces Delisting from Nasdaq and SEC Deregistration
PHILADELPHIA , Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to pr...
Carisma Therapeutics Quarterly report: Q3 2025
Carisma Therapeutics has published its Q3 2025 quarterly earnings report on November 12, 2025.
Why Is Carisma Therapeutics Stock (CARM) Up 165% Today?
Carisma Therapeutics stock rallied on Tuesday after the company announced an update to its merger with OrthoCellix.
Carisma Therapeutics Quarterly report: Q2 2025
Carisma Therapeutics has published its Q2 2025 quarterly earnings report on August 27, 2025.
Carisma Therapeutics, OrthoCellix enter definitive merger agreement
Carisma Therapeutics (CARM) and OrthoCellix, a wholly-owned subsidiary of Ocugen (OCGN), announced that they have entered into a definitive merger agreement to combine the companies in an all-stock tr...
Carisma Therapeutics Stock (CARM) Retreats 35% After a Massive Rally
Carisma Therapeutics stock fell on Wednesday as the company’s shares retreated from a massive rally on Tuesday.
Is the 250% Carisma Therapeutics Stock (CARM) Surge a Sucker’s Rally?
Carisma Therapeutics stock rocketed higher on Tuesday but this might be a case of a sucker’s rally.
Carisma Therapeutics Quarterly report: Q1 2025
Carisma Therapeutics has published its Q1 2025 quarterly earnings report on May 12, 2025.
Carisma Therapeutics price target lowered to $1 from $12 at D. Boral Capital
D. Boral Capital lowered the firm’s price target on Carisma Therapeutics (CARM) to $1 from $12 and keeps a Buy rating on the shares after the company announced a strategic…
Carisma Therapeutics Provides Corporate Updates
Company to explore strategic alternatives to advance liver fibrosis and oncology assets and reduce operational cash burn PHILADELPHIA , March 31, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq...
Carisma Therapeutics Annual report: Q4 2024
Carisma Therapeutics has published its Q4 2024 annual report on March 31, 2025.
Carisma Therapeutics Transcript: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
The company is advancing engineered myeloid cell therapies, with a focus on mesothelin-targeted CT-1119 for solid tumors and TIM4-based CT-2401 for liver fibrosis. Key milestones include a Phase 1 trial for CT-1119 and a development candidate for fibrosis, with strong industry partnerships supporting progress.
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
PHILADELPHIA , Feb. 19, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky...
Carisma Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025
The conference detailed advances in CAR-macrophage therapies for oncology, fibrosis, and autoimmune diseases, highlighting a shift to in vivo reprogramming and key partnerships. Major milestones include upcoming clinical trials for CT2401 and CT1119, and ongoing collaboration with Moderna on multiple targets.
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
PHILADELPHIA , Feb. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, Presi...
Carisma Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor downgraded Carisma Therapeutics (CARM) to Neutral from Buy without a price target after the company said it would be discontinuing development of its lead progr...
Carisma investors should ‘stay the course,’ says D. Boral Capital
D. Boral Capital analyst Jason Kolbert says investors should “stay the course” on Carisma Therapeutics (CARM) amid the rating downgrades following the company’s announcement to discontinue development...
Carisma Therapeutics downgraded to Neutral from Outperform at Baird
Baird downgraded Carisma Therapeutics (CARM) to Neutral from Outperform with a price target of $1, down from $10. Carisma earlier this week announced plans to undergo a strategic restructuring, shifti...
Carisma Therapeutics downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Carisma Therapeutics (CARM) to In Line from Outperform with a price target of 70c, down from $4. With its second major pipeline shift this year, Carisma is…
Carisma Therapeutics downgraded to Neutral from Buy at BTIG
BTIG downgraded Carisma Therapeutics (CARM) to Neutral from Buy and removed the firm’s price target after Carisma announced the “difficult decision” to discontinue their lead HER-2 monocyte program CT...
Carisma Therapeutics price target lowered to $12 from $24 at D. Boral Capital
D. Boral Capital lowered the firm’s price target on Carisma Therapeutics (CARM) to $12 from $24 and keeps a Buy rating on the shares after the company announced it is…
Carisma Therapeutics announces restructuring, 34% workforce reduction
Carisma Therapeutics (CARM) announced a strategic reprioritization of its pipeline, cessation of development of CT-0525, and a reduction in the workforce by 34%. These measures will enable Carisma to ...
Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline
Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies Development of CT-0525 to be discontinued; workforce reduced b...